RT Journal Article
SR Electronic
T1 A Spatial Comparison of Molecular Features Associated with Resistance to Pembrolizumab in BCG Unresponsive Bladder Cancer
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.11.28.23299093
DO 10.1101/2023.11.28.23299093
A1 Meghani, Khyati
A1 Frydenlund, Noah
A1 Yu, Yanni
A1 Choy, Bonnie
A1 Meeks, Joshua J.
YR 2023
UL http://medrxiv.org/content/early/2023/11/30/2023.11.28.23299093.abstract
AB Background Intravenous immune checkpoint inhibition achieves a 40% three-month response in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS). Yet only half of early responders will continue to be disease free by 12 months, and resistance mechanisms are poorly defined.Objective We assessed the molecular features associated with response to immunotherapy in BCG unresponsive non-muscle invasive bladder cancers treated with pembrolizumab.Design, Setting, and Participants We performed digital spatial profiling (DSP) of BCG unresponsive NMIBC tumors before and after IV pembrolizumab therapy.Intervention Pembrolizumab was administered intravenously in patients with NMIBC at the time of recurrence after BCG therapy. Biopsies were obtained before starting IV pembrolizumab and three months post-treatment.Outcomes and Statistical Analysis Spatial gene expression profiling of the tumor niche pre- and post IV pembrolizumab.Results and Limitations We evaluated 119 regions of interest (ROIs) from five patients, which included 60 epithelial (PanCK+) and 59 stromal segments (PanCK-). ROIs from responders had distinct expression signatures from non-responders for both the tumor and TME. Responders were more likely to have a dynamic change in expression after pembrolizumab than non-responders. A major limitation of this study was the number of patients evaluated.Conclusion For the first time, we have identified distinct expression signatures associated with response and resistance to IV pembrolizumab in NMIBCs. Further research with more patients and alternative checkpoint inhibitors is essential to validate our findings.Patient Summary We identify the molecular features of tumors associated with response to pembrolizumab for patients with BCG unresponsive NMIBCs.Competing Interest StatementKM: None NF: Research Funding from the AUA Foundation JM advisory board/consulting: Merck, AstraZeneca, Incyte, Janssen, BMS, UroGen, Prokarium, Imvax, Pfizer, Seagen/Astellas, Ferring; Research Funding: VHA, NIH, DoD, Compensation for talks/educational courses: AUA, OncLive, Olympus, UroToday; Clinical Trials: SWOG, Genentech, Merck, AstraZeneca Funding StatementThis study was funded by the Merck Investigator Studies Program (MISP) and the Robert H. Lurie Cancer Center. JM is supported by grants from the VHA BX005599 and BX003692. This work was supported by the Northwestern University RHLCCC Flow Cytometry Facility and the Cancer Center Support Grant (NCI CA060553).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All studies were approved by Northwestern IRBI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors